DRC receives 70,000 Ervebo vaccine doses, with 20,000 for a Phase III trial against Bundibugyo virus and 50,000 for frontline and health workers.

WHO experts say early evidence, including animal studies, suggests Ervebo could offer some protection—and the new trial will seek to establish whether that protection extends to…

Imunizante aprovado mira a cepa Zaire, não a Bundibugyo